Flag of the European Union EU Clinical Trials Register Help

Clinical trials for gardasil

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    64 result(s) found for: gardasil. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2019-003135-36 Sponsor Protocol Number: CYD67 Start Date*: 2019-10-31
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia
    Medical condition: Dengue Fever Dengue Hemorrhagic Fever Human Papillomavirus Disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-000764-85 Sponsor Protocol Number: V501-024-00 Start Date*: 2006-05-10
    Sponsor Name:Merck & Co., Inc
    Full Title: A Open-label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of GARDASIL™ Given Concomitantly with REPEVAX™ in Healthy Adolescents 11-17 Years of Age
    Medical condition: Prevention of Human Papillomavirus Infection
    Disease: Version SOC Term Classification Code Term Level
    7.0 10063001 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002332-73 Sponsor Protocol Number: 2020/CHU/05 Start Date*: 2020-07-16
    Sponsor Name:Centre Hospitalier Universitaire de la Réunion
    Full Title: Promotion of sexual health and promotion of a papillomavirus vaccination program in middle school
    Medical condition: Gardasil 9 is indicated for the active immunization of individuals from 9 years old against diseases due to HPV
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005581-19 Sponsor Protocol Number: 719_OPBG_2014 Start Date*: 2014-07-31
    Sponsor Name:Bambino Gesù Children’s Hospital
    Full Title: Immune memory to HPV induced by Gardasil in girls and boys
    Medical condition: Healthy subjects undergoing voluntary vaccination
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2014-005717-23 Sponsor Protocol Number: V501-018-00 Start Date*: 2015-12-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL™ (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL™ at 9-18 Years of Age
    Medical condition: HPV
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003852-13 Sponsor Protocol Number: V504-001-00 Start Date*: 2007-11-09
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine (V504) Administered Concomitantly with GARDASIL...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52, an...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063001 Human papilloma virus infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004581-16 Sponsor Protocol Number: V501-030 Start Date*: 2015-04-02
    Sponsor Name:Merck Sharp & Dohme (China) Ltd.
    Full Title: An Immunogenicity and Safety Study of GARDASIL™ in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years
    Medical condition: Prevention of HPV types 6, 11, 16 and 18 related cervical cancer, vulvar, vaginal pre-cancers, low-grade, pre-cancerous lesions, and genital warts in Chinese female subjects aged 9 to 45 years and ...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002083-13 Sponsor Protocol Number: HPVfollowup Start Date*: 2016-07-21
    Sponsor Name:Public Health England
    Full Title: An observational follow up study of a randomised parallel group phase IV study to evaluate the duration of the immune response to vaccine and non-vaccine HPV types in UK adolescent females who rece...
    Medical condition: No specific medical condition - immune reponses to HPV vaccination.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10071146 Human papilloma virus immunisation PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004662-33 Sponsor Protocol Number: C/39/2018 Start Date*: 2019-07-12
    Sponsor Name:Imperial College London
    Full Title: NOVEL: Nonavalent HPV vaccine after local conservative treatment for cervical pre-invasive disease - a randomised controlled trial
    Medical condition: Cervical intra-epithelial neoplasia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008605-22 Sponsor Protocol Number: 1.0 Start Date*: 2009-03-13
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Dermatologie
    Full Title: Determination of the human papillomavirus (HPV)-specific antibody status in oral fluids of individuals vaccinated with a quadrivalent HPV vaccine
    Medical condition: Healthy women aged 18-26
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065136 Human papilloma virus exposure LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002340-90 Sponsor Protocol Number: HPV-Xneutra-001 Start Date*: 2013-06-26
    Sponsor Name:Ghent University Hospital
    Full Title: Study of the molecular mechanisms underlying the cross-neutralizing capacity of AS04-adjuvanted HPV vaccine (Cervarix®) in comparison with the aluminiumhydroxyphosphate sulphate adjuvanted HPV vacc...
    Medical condition: vaccin against the human papillomavirus
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10046859 Vaccination LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003528-39 Sponsor Protocol Number: V503-001 Start Date*: 2007-11-15
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavi...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-006773-32 Sponsor Protocol Number: HPV_CSP01 Start Date*: 2009-05-20
    Sponsor Name:Health Protection Agency
    Full Title: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines
    Medical condition: This study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate wheth...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058580 Human papilloma virus serology test LLT
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004007-13 Sponsor Protocol Number: NCT-2010-1090 Start Date*: 2013-09-06
    Sponsor Name:Deutsches Krebsforschungszentrum (DKFZ
    Full Title: A randomized, placebo-controlled, phase IIIb HPV vaccination trial with Gardasil® in patients with recurrent condylomata acuminata
    Medical condition: Patients with recurrrent external condylomata acuminata located at the following genital regions: labia minora and majora, introitus vaginae, clitoris, prepuce, glans penis, coronal sulcus and fren...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016515 10010295 Condylomata acuminatum LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000110-35 Sponsor Protocol Number: V501-046 Start Date*: 2017-01-11
    Sponsor Name:Merck & Co., Inc.
    Full Title: Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa.
    Medical condition: Vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023393-39 Sponsor Protocol Number: GDS01C Start Date*: 2011-01-13
    Sponsor Name:Sanofi Pasteur MSD S.N.C
    Full Title: A Randomized, Double-Blinded, Controlled with GARDASIL® (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Toler...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) Types 6, ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066416 Vulvovaginal human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: FI (Completed) BE (Completed) SE (Completed) ES (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002137-38 Sponsor Protocol Number: B1971011(6108A1-2007) Start Date*: 2013-05-23
    Sponsor Name:Pfizer Inc
    Full Title: A Phase 2, Randomized, ACTIVE-CONTROLLED, observer-blinded Trial, to Assess the Safety, Tolerability, and Immunogenicity of Gardasil® (HPV) Vaccine and BIVALENT RLP2086 Vaccine When Administered Co...
    Medical condition: Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10004049 Bacterial meningitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-015500-26 Sponsor Protocol Number: V503-006 Start Date*: 2010-03-24
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like P...
    Medical condition:
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: SE (Completed) DK (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001205-33 Sponsor Protocol Number: V503-017 Start Date*: 2019-03-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam
    Medical condition: Prevention of cervical, vulvar, vaginal, and anal cancers and related precancers, and anogenital warts caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002193-23 Sponsor Protocol Number: HLS04/2011 Start Date*: 2011-09-27
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Long term Immunogenicity of Quadrivalent Human Papillomavirus vaccine (Gardasil) in HIV-infected adolescents and young adults vs. healthy adolescents and young adults: non-randomized controlled cli...
    Medical condition: HIV+ teenagers and young adults versus HIV-negative subjects: high-risk population for HPV-related disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 09:18:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA